Edward O. Lanphier

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

The Biotechnology Institute is a non-profit organization, which engages in designing and managing programs about biotechnology research. Its programs include BioGENEius Challenges, leadership awards, and Adopt-A-School. The company was founded in 1998 and is headquartered in Washington, DC.

Gerostate Alpha, Inc. develops pharmaceuticals for treating aging and age-related diseases. The company was founded by Simon Melov, Gordon Lithgow and Mark Lucanic in June 2018 and is headquartered in Novato, CA.

Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland.

Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA

Part of Insmed, Inc., Celtrix Pharmaceuticals, Inc. researches and develops potential therapeutic products. The company is based in Santa Clara, CA.

Biotherapeutics, Inc. operates as a pre-clinical stage company which develops small-molecule drugs to treat inflammation and type 2 diabetes. Its scientific foundation is anchored on informatics and computer modeling-enabled drug development with significant animal pharmacology validation. The company was founded by Josep Bassaganya-Riera in 2008 and is headquartered in Blacksburg, VA.